Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder

Bipolar Disorders

Volumn 17, Issue 3, 2015, Pages 257-268

  Munkholm, Klaus ^a   Poulsen, Henrik Enghusen ^b,c   Kessing, Lars Vedel ^a   Vinberg, Maj ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

8 oxodG; 8 oxoGuo; Bipolar disorder; Nucleosides; Oxidation; Urinary marker

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 OXO 7,8 DIHYDROGUANOSINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DNA; GUANINE DERIVATIVE; LITHIUM; NEUROLEPTIC AGENT; RNA; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; 8-HYDROXYGUANOSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; BIOLOGICAL MARKER; DEOXYGUANOSINE; GUANOSINE;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENETIC DAMAGE; GLUCOSE BLOOD LEVEL; GUANINE DERIVATIVE URINE LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR DEPRESSION; MALE; MANIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RNA DAMAGE; URINALYSIS; URINARY EXCRETION; URINE LEVEL; YOUNG MANIA RATING SCALE; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; GENETICS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; URINE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEOXYGUANOSINE; DNA; DNA DAMAGE; FEMALE; GUANOSINE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; RNA; YOUNG ADULT;

EID: 84928209473     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12245     Document Type: Article

References (54)

1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005; 293: 2528-2530.
2. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131: 101-104.
3. Pompili M, Gonda X, Serafini G et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord 2013; 15: 457-490.
4. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181.
5. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-387.
6. Vinberg M, Madsen M, Breum L, Kessing LV, Fink-Jensen A. Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nord J Psychiatry 2012; 66: 142-145.
7. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord 2008; 110: 149-155.
8. Leboyer M, Soreca I, Scott J et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012; 141: 1-10.
9. Fries GR, Pfaffenseller B, Stertz L et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012; 14: 667-675.
10. Munkholm K, Vinberg M, Berk M, Kessing LV. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord 2012; 14: 684-696.
11. Gigante AD, Young LT, Yatham LN et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 2011; 14: 1075-1089.
12. Andreazza AC, Kauer-Sant'anna M, Frey BN et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111: 135-144.
13. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-876.
14. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 676-692.
15. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764-785.
16. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
17. Broedbaek K, Siersma V, Henriksen T et al. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. Diabetes Care 2013; 36: 669-676.
18. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol 2008; 23: 381-390.
19. Lovell MA, Soman S, Bradley MA. Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. Mech Ageing Dev 2011; 132: 443-448.
20. Poulsen HE, Specht E, Broedbaek K et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 2012; 52: 1353-1361.
21. Buttner N, Bhattacharyya S, Walsh J, Benes FM. DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr Res 2007; 93: 33-41.
22. Andreazza AC, Frey BN, Erdtmann B et al. DNA damage in bipolar disorder. Psychiatry Res 2007; 153: 27-32.
23. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 2013; 16: 1505-1512.
24. Che Y, Wang JF, Shao L, Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010; 35: 296-302.
25. Barregard L, Møller P, Henriksen T et al. Human and methodological sources of variability in the measurement of urinary 8-oxo-7, 8-dihydro-2'-deoxyguanosine. Antioxid Redox Signal 2013; 18: 2377-2391.
26. Henriksen T, Hillestrom PR, Poulsen HE, Weimann A. Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-2'-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandem mass spectrometry. Free Radic Biol Med 2009; 47: 629-635.
27. Weimann A, Belling D, Poulsen HE. Quantification of 8-oxo-guanine and guanine as the nucleobase, nucleoside and deoxynucleoside forms in human urine by high-performance liquid chromatography-electrospray tandem mass spectrometry. Nucleic Acids Res 2002; 30: E7.
28. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 16-27.
29. Wing JK, Babor T, Brugha T et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593.
30. Angst J, Adolfsson R, Benazzi F et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005; 88: 217-233.
31. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
32. Williams JBW. Structural interview guidelines for the Hamilton Depression Rating Scale. In: Bech P, Coppen A eds. The Hamilton Scales. Berlin: Springer, 1990: 48-63.
33. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
34. Garratt LW, Mistry V, Singh R et al. Interpretation of urinary 8-oxo-7, 8-dihydro-2'-deoxyguanosine is adversely affected by methodological inaccuracies when using a commercial ELISA. Free Radic Biol Med 2010; 48: 1460-1464.
35. Poulsen HE, Nadal LL, Broedbaek K, Nielsen PE, Weimann A. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochim Biophys Acta 2014; 1840: 801-808.
36. Deng XS, Tuo J, Poulsen HE, Loft S. Prevention of oxidative DNA damage in rats by brussels sprouts. Free Radic Res 1998; 28: 323-333.
37. Prieme H, Loft S, Klarlund M, Gronbaek K, Tonnesen P, Poulsen HE. Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7, 8-dihydro-2'-deoxyguanosine excretion. Carcinogenesis 1998; 19: 347-351.
38. Satterlee JS, Barbee S, Jin P et al. Noncoding RNAs in the brain. J Neurosci 2007; 27: 11856-11859.
39. Kong Q, Lin CL. Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci 2010; 67: 1817-1829.
40. Jorgensen A, Broedbaek K, Fink-Jensen A et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res 2013; 209: 417-423.
41. Jorgensen A, Krogh J, Miskowiak K et al. Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. J Affect Disord 2013; 149: 355-362.
42. McEwen BS. Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging. Metabolism 2003; 52: 10-16.
43. Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav 2012; 106: 46-50.
44. Schneck CD, Miklowitz DJ, Calabrese JR et al. Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry 2004; 161: 1902-1908.
45. McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci USA 2012; 109 (Suppl. 2): 17180-17185.
46. Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-1354.
47. Kessing LV, Andersen PK. The effect of episodes on recurrence in affective disorder: a case register study. J Affect Disord 1999; 53: 225-231.
48. Berk M, Conus P, Lucas N et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007; 9: 671-678.
49. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 441-445.
50. Maes M, Yirmyia R, Noraberg J et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27-53.
51. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013; 27: 135-153.
52. Andreazza AC, Kauer-Sant'Anna M, Frey BN et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 2008; 33: 516-524.
53. Miljevic C, Nikolic-Kokic A, Nikolic M et al. Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study). Hum Psychopharmacol 2013; 28: 1-6.
54. Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012; 2012: 609421.